Your shopping cart is currently empty

M3258 is an immunoproteasome subunit LMP7 (β5i) inhibitor, with an IC50 of 3.6 nM for LMP7 and 3.4 nM at the cellular level. In a multiple myeloma xenograft model, M3258 exhibits significant antitumor activity. In multiple myeloma cells, M3258 significantly and persistently inhibits LMP7 activity and ubiquitinated protein turnover in tumor tissues, further inducing apoptosis.


| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $129 | - | In Stock | |
| 5 mg | $322 | - | In Stock | |
| 10 mg | $488 | - | In Stock | |
| 25 mg | Preferential | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $232 | - | In Stock |
| Description | M3258 is an immunoproteasome subunit LMP7 (β5i) inhibitor, with an IC50 of 3.6 nM for LMP7 and 3.4 nM at the cellular level. In a multiple myeloma xenograft model, M3258 exhibits significant antitumor activity. In multiple myeloma cells, M3258 significantly and persistently inhibits LMP7 activity and ubiquitinated protein turnover in tumor tissues, further inducing apoptosis. |
| Targets&IC50 | LMP7:2–37 nM |
| In vitro | M3258 inhibits human LMP7 with an IC50 of 4.1 nM, while showing much weaker inhibitory activity against the constitutive proteasome subunit β5, with an average IC50 of 2519 nM.It also effectively inhibits LMP7 activity in human multiple myeloma cell lines MM.1S and U266B1, as well as in human, rat, and canine peripheral blood mononuclear cells (PBMCs), with IC50 values ranging from 2 to 37 nM. In MM.1S cells, M3258 increases ubiquitinated protein levels by more than 4-fold, with an EC50 of 1980 nM, indicating that the compound disrupts the normal function of the immunoproteasome.Furthermore, M3258 induces apoptosis by activating caspase-3/7 activity, with an EC50 of 420 nM and an apoptosis induction fold of over 3.5. It also significantly reduces the viability of MM.1S cells, with an IC50 of 367 nM [2]. |
| In vivo | M3258 exhibits superior antitumor efficacy compared to the marketed non-selective proteasome inhibitors bortezomib and ixazomib in specific multiple myeloma and mantle cell lymphoma xenograft models at doses of 1 mg/kg and 10 mg/kg [2]. |
| Synonyms | LMP7-IN-1 |
| Molecular Weight | 329.16 |
| Formula | C17H20BNO5 |
| Cas No. | 2285330-15-4 |
| Smiles | C([C@H](NC(=O)[C@H]1[C@]2(O[C@@](C1)(CC2)[H])[H])B(O)O)C=3C=4C(OC3)=CC=CC4 |
| Relative Density. | 1.328 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 200 mg/mL (607.61 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (10.03 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.